Investor Backing & Capital Strength:
The $30M Series B led by Andreessen Horowitz on February 26, 2025, with total funding cited at $50M, supplies meaningful capital to scale. Portfolio inclusion and public “doubling down” commentary from a16z reflect strong external validation.
Market Expansion:
Company communications cite 81.8% more clinics and 163% more patients year over year, ~1.5M automated claims, and claims processed in all 50 states. Materials also note growth from an ABA beachhead into PT, ENT/Allergy, and plans for home health, long‑term care, and substance use disorders.
Innovation-Driven Growth:
The platform is positioned as AI‑native RCM with reported ~93–95% first‑pass paid rates and one of the largest specialty claims datasets across ABA/SLP/OT/PT. Investor notes and case materials tie these capabilities to improved collections and denial reduction, supporting adoption.
